An observational study in Acute Lymphoblastic Leukemia, sponsored by Hospital Regional de Alta Especialidad del Bajio. Recruiting at 1 site in Mexico. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Hospital Regional de Alta Especialidad del Bajio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico — 7 open to participants now, 11 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Mexico.
Among the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico, this one is the only one that started in 2024, is one of 8 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 30th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →7 of the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico are open now. Recruiting first, the newest first:
Hospital General de Mexico · Sites in Mexico
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 16–60
Coordinación de Investigación en Salud, Mexico · Sites in Mexico
Ages 5–17
St. Anna Kinderkrebsforschung · Sites in Mexico, Argentina, Australia and 28 more countries
Ages 1 mo–18 yrs
National Institute of Pediatrics, Mexico · Sites in Mexico
Ages 6–17
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 8 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 70 across the 26 interventional studies, 50 across the 8 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 34 have an industry lead sponsor. The 10 most frequent:
Hospital Regional de Alta Especialidad del Bajio is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Hospital Regional de Alta Especialidad del Bajio has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT06291428Hospital Regional de Alta Especialidad del BajioRaman Spectroscopy Compared to Flow Cytometry | 2026-12-30 |
| NCT06886074Hospital Universitario Dr. Jose E. GonzalezEfficacy of Short-course Blinatumomab for MRD Erradication in B-ALL | 2027-01 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The detection of MRD is associated with an increased risk of relapse and adverse prognosis in all patient groups diagnosed with acute lymphoblastic leukemia (ALL). However, it has a sensitivity level that detects one leukemic cell in 10,000 normal cells, along with other disadvantages such as the need for a panel of fluorescent antibodies for MRD detection, and its measurement is not standardized in many centers. New determination techniques may be necessary for MRD evaluation. Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect).
Objectives:
MAIN OBJECTIVE:
To evaluate the presence of MRD in patients with ALL by comparing a standard evaluation method using flow cytometry with a new proposed method using Raman spectroscopy.
SPECIFIC OBJECTIVES:
Study Design:
An observational, cross-sectional, comparative, and diagnostic test study will be conducted on bone marrow aspirate samples from adult and pediatric ALL patients to evaluate the presence of MRD using Raman spectroscopy, comparing the results of this technique with those obtained using flow cytometry. As a diagnostic test study, sensitivity, specificity, positive predictive value, and negative predictive value will be evaluated. The study will be conducted on adult and pediatric patients diagnosed with acute lymphoblastic leukemia treated at the hemato-oncology department of the UMAE No. 1 National Medical Center Bajio and the UMAE Hospital Gynecology-Pediatrics No. 48.
Inclusion Criteria:
Patients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study. Their results will be evaluated using the gold standard, flow cytometry, and compared with results obtained through Raman spectroscopy.
The assessment of measurable residual disease (MRD) is a frequent practice in the management of acute lymphoblastic leukemia (ALL). The detection of MRD is associated with an increased risk of relapse and adverse prognosis in all patient groups diagnosed with ALL. The three approved methods for MRD measurement are flow cytometry, polymerase chain reaction (PCR) of specific mutations, and next-generation sequencing (NGS). Of these, flow cytometry is the most used method in clinical practice. However, it has a sensitivity level that detects one leukemic cell in 10,000 normal cells, along with other disadvantages such as the need for a panel of fluorescent antibodies for MRD detection, and its measurement is not standardized in many centers. New determination techniques may be necessary for MRD evaluation. Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
Objectives:
MAIN OBJECTIVE:
To evaluate the presence of MRD in patients with ALL by comparing a standard evaluation method using flow cytometry with a new proposed method using Raman spectroscopy.
SPECIFIC OBJECTIVES:
Study Design:
An observational, cross-sectional, comparative, and diagnostic test study will be conducted on bone marrow aspirate samples from adult and pediatric ALL patients to evaluate the presence of MRD using Raman spectroscopy, comparing the results of this technique with those obtained using flow cytometry. As a diagnostic test study, sensitivity, specificity, positive predictive value, and negative predictive value will be evaluated. The study will be conducted on adult and pediatric patients diagnosed with acute lymphoblastic leukemia treated at the hemato-oncology department of the UMAE No. 1 National Medical Center Bajio and the UMAE Hospital Gynecology-Pediatrics No. 48.
Inclusion Criteria:
Patients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study. Their results will be evaluated using the gold standard, flow cytometry, and compared with results obtained through Raman spectroscopy.
Acute lymphoblastic leukemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
Diagnostic Test: Raman spectroscopy
Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
Diagnostic Test: Raman spectroscopy
Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
measurable residual disease
To evaluate the presence of MRD in patients with ALL by comparing a standard evaluation method using flow cytometry with a new proposed method using Raman spectroscopy.
Time frame: up to 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 26 months is below that.
Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Hospital Regional de Alta Especialidad del Bajio